Immunotherapy Study for Surgically Resected Pancreatic Cancer

Full Title	A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer
Protocol Number	NLG0405
clinicaltrials.gov	http://clinicaltrials.gov/show/NCT01072981
Principal Investigator(s)	Clifford S Cho, MD
Division	General Surgery
Status	Recruiting
Description	The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.